<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Relatively little information is available on the incidence of <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">secondary cancer</z:e> in non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this long-term follow-up study was to determine the incidence, the time free of second <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, and risk factors for developing <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">secondary cancer</z:e> in a homogeneous group of patients with non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>DESIGN AND METHODS: We evaluated a total of 563 patients with indolent non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> enrolled in Gruppo Italiano Studio Linfomi trials from 1988 to 2003 </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: After a median follow-up of 62 months, 39 patients (6.9%) developed <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">secondary cancer</z:e>: 12 <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>/<z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, and 27 solid <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The overall standardized incidence ratio of <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">secondary malignancy</z:e> in patients with non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> was higher than the risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> in the general population </plain></SENT>
<SENT sid="5" pm="."><plain>The standardized incidence ratio was elevated in male patients and in patients under 65 years old at first treatment </plain></SENT>
<SENT sid="6" pm="."><plain>Overall, the cumulative incidence of <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">secondary cancer</z:e> at 12 years was 10.5%, after correction in a competing-risk model </plain></SENT>
<SENT sid="7" pm="."><plain>Univariate and multivariate Cox regression analyses showed that older age at the time of diagnosis, male sex, and fludarabine-containing therapy had significant negative impacts on the time free of second <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: We have identified subgroups of non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients with increased standardized incidence ratios of <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">secondary malignancy</z:e> and variables that have a negative impact on the time free of second <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>This information could help physicians to select the most appropriate treatments </plain></SENT>
<SENT sid="10" pm="."><plain>Finally, taking into account the possible occurrence of secondary <z:hpo ids='HP_0002664'>neoplasia</z:hpo>, long-term monitoring must be considered </plain></SENT>
</text></document>